Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.

Article  PubMed  Google Scholar 

Bhatt JM. The epidemiology of neuromuscular diseases. Neurol Clin. 2016;34(4):999–1021.

Article  PubMed  Google Scholar 

Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics. Front Immunol. 2020;11:212.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hughes BW, Moro Casillas ML, Kaminski HJ. Pathophysiology of myasthenia gravis. Semin Neurol. 2004;24(1):21–30.

Article  PubMed  Google Scholar 

Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current treatment of myasthenia gravis. J Clin Med. 2022;11(6):1597.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018;11:1756285617749134.

Article  PubMed  PubMed Central  Google Scholar 

Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15(2):113–24.

Article  PubMed  Google Scholar 

Dalakas MC. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev Clin Immunol. 2022;18(7):691–701.

Article  CAS  PubMed  Google Scholar 

Lascano AM, Lalive PH. Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev. 2021;20(1): 102712.

Article  CAS  PubMed  Google Scholar 

Song Z, Zhang J, Meng J, Jiang G, Yan Z, Yang Y, et al. Different monoclonal antibodies in myasthenia gravis: a Bayesian network meta-analysis. Front Pharmacol. 2021;12: 790834.

Article  CAS  PubMed  Google Scholar 

Saccà F, Pane C, Espinosa PE, Sormani MP, Signori A. Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. Eur J Neurol. 2023;30(12):3854–67.

Article  PubMed  Google Scholar 

Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology. 2005;64(11):1968–70.

Article  CAS  PubMed  Google Scholar 

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane; 2023. www.training.cochrane.org/handbook. Accessed 26 Oct 2023.

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928.

Article  PubMed  PubMed Central  Google Scholar 

Mavridis D, Salanti G. A practical introduction to multivariate meta-analysis. Stat Methods Med Res. 2013;22(2):133–58.

Article  PubMed  Google Scholar 

Tonin FS, Rotta I, Mendes AM, Pontarolo R. Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Pract (Granada). 2017;15(1):943.

Article  PubMed  PubMed Central  Google Scholar 

Melsen WG, Bootsma MC, Rovers MM, Bonten MJ. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. Clin Microbiol Infect. 2014;20(2):123–9.

Article  CAS  PubMed  Google Scholar 

Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012;3(2):98–110.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7–8):932–44.

Article  CAS  PubMed  Google Scholar 

Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163–71.

Article  PubMed  Google Scholar 

Pharmaceuticals N. A Multi-center, Randomized, Double-blind, placebo-controlled, parallel group study to preliminarily evaluate the safety, tolerability, pharmacokinetics and efficacy of CFZ533 in patients with moderate to severe myasthenia gravis [Internet]. clinicaltrials.gov;. 2020 Dec [cited 2022 Jan 5]:Report No.: NCT02565576.

Guptill J, Antozzi C, Bril V, Gamez J, Meuth SG, Blanco JLM, et al. Vivacity-MG: A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of nipocalimab administered to adults with generalized myasthenia gravis (2157). Neurology. 2021;96(15 Supplement):2157.

Article  Google Scholar 

Pharmaceuticals A. A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of ravulizumab in complement-inhibitor-naïve adult patients with generalized myasthenia gravis[Internet]. clinicaltrials.gov. 2021 Sep [cited 2021 Nov 18]:Report No.:NCT03920293.

Howard JF Jr, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, et al. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol. 2020;77(5):582–92.

Article  PubMed  Google Scholar 

Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA, et al. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol. 2022;79(11):1105–12.

Article  PubMed  PubMed Central  Google Scholar 

Wang L, Huan X, Xi JY, Wu H, Zhou L, Lu JH, et al. Immunosuppressive and monoclonal antibody treatment for myasthenia gravis: a network meta-analysis. CNS Neurosci Ther. 2019;25(5):647–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nowak RJ, Coffey CS, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT, et al. Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology. 2021;98(4):e376–89.

Google Scholar 

Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ, Bassiri A, et al. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology. 2018;90(16):e1425–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schneider-Gold C, Gilhus NE. Advances and challenges in the treatment of myasthenia gravis. Ther Adv Neurol Disord. 2021;14:17562864211065406.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di Stefano V, Lupica A, Rispoli MG, Di Muzio A, Brighina F, Rodolico C. Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry. 2020;91(4):392–5.

Article  PubMed  Google Scholar 

Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82(8):865–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169–81.

Article  CAS  PubMed  Google Scholar 

Howard JF Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48(1):76–84.

Article  CAS  PubMed  Google Scholar 

Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976–86.

Article  CAS  PubMed  Google Scholar 

Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60(1):14–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nelke C, Schroeter CB, Stascheit F, Pawlitzki M, Regner-Nelke L, Huntemann N, et al. Eculizumab versus rituximab in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2022;93(5):548–54.

Article  PubMed  Google Scholar 

Menon D, Barnett C, Bril V. Novel Treatments in myasthenia gravis. Front Neurol. 2020;11:538.

Article  PubMed  PubMed Central  Google Scholar 

Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bril V, Benatar M, Andersen H, Vissing J, Brock M, Greve B, et al. Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial. Neurology. 2021;96(6):e853–65.

Article  CAS  PubMed  PubMed Central